MX2019014758A - Productos radiofarmaceuticos, agentes de radioimagenologia, y uso de los mismos. - Google Patents

Productos radiofarmaceuticos, agentes de radioimagenologia, y uso de los mismos.

Info

Publication number
MX2019014758A
MX2019014758A MX2019014758A MX2019014758A MX2019014758A MX 2019014758 A MX2019014758 A MX 2019014758A MX 2019014758 A MX2019014758 A MX 2019014758A MX 2019014758 A MX2019014758 A MX 2019014758A MX 2019014758 A MX2019014758 A MX 2019014758A
Authority
MX
Mexico
Prior art keywords
radiopharmaceuticals
compounds
radioimaging agents
useful
coordinated
Prior art date
Application number
MX2019014758A
Other languages
English (en)
Inventor
Nicholas Alan Zia
Paul Stephen Donnelly
Original Assignee
Clarity Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902151A external-priority patent/AU2017902151A0/en
Application filed by Clarity Pharmaceuticals Ltd filed Critical Clarity Pharmaceuticals Ltd
Publication of MX2019014758A publication Critical patent/MX2019014758A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08—Copper compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)

Abstract

La presente invención se refiere a compuestos que son útiles como productos radiofarmacéuticos y agentes de radioimagenología que tiene un agente quelador de radionúclido. Estos compuestos coordinados son útiles en radioterapia e imagenología de diagnóstico. La invención también se refiere a métodos de diagnosis, prognosis y terapia que utilizan los compuestos no coordinados y radiomarcados de la invención.
MX2019014758A 2017-06-06 2018-06-05 Productos radiofarmaceuticos, agentes de radioimagenologia, y uso de los mismos. MX2019014758A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017902151A AU2017902151A0 (en) 2017-06-06 Radiopharmaceuticals, radioimaging agents, and uses thereof
PCT/AU2018/050555 WO2018223180A1 (en) 2017-06-06 2018-06-05 Radiopharmaceuticals, radioimaging agents, and uses thereof

Publications (1)

Publication Number Publication Date
MX2019014758A true MX2019014758A (es) 2022-02-28

Family

ID=64565650

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014758A MX2019014758A (es) 2017-06-06 2018-06-05 Productos radiofarmaceuticos, agentes de radioimagenologia, y uso de los mismos.
MX2022002401A MX2022002401A (es) 2017-06-06 2019-12-06 Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022002401A MX2022002401A (es) 2017-06-06 2019-12-06 Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.

Country Status (15)

Country Link
US (4) US10975089B2 (es)
EP (2) EP3634965B1 (es)
JP (2) JP7144451B2 (es)
KR (1) KR102644075B1 (es)
CN (2) CN115322244A (es)
AU (1) AU2018280338B2 (es)
BR (1) BR112019025881A2 (es)
CA (1) CA3066525A1 (es)
DK (1) DK3634965T3 (es)
ES (1) ES2943458T3 (es)
FI (1) FI3634965T3 (es)
MX (2) MX2019014758A (es)
PL (1) PL3634965T3 (es)
PT (1) PT3634965T (es)
WO (1) WO2018223180A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
CN112423744A (zh) * 2018-04-11 2021-02-26 透明医药有限公司 用于放射疗法和诊断成像的制剂和试剂盒
CA3137773A1 (en) * 2019-05-24 2020-12-03 Clarity Pharmaceuticals Limited Formulations of psma imaging agents
AU2020296488A1 (en) * 2019-06-21 2022-01-20 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
EP4055020A4 (en) * 2019-11-08 2024-01-10 Univ Queensland RADIOLABELED TARGETING LIGANDS
TW202200214A (zh) * 2020-04-29 2022-01-01 義大利商先進艾斯雷特應用（義大利）公司 放射性標記psma結合配位體的方法及其套組
US20240050600A1 (en) * 2020-08-14 2024-02-15 Clarity Pharmaceuticals Ltd Radiopharmaceuticals, uses thereof, and methods for the production thereof
US20240018099A1 (en) * 2020-11-19 2024-01-18 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
WO2022123462A1 (en) * 2020-12-09 2022-06-16 3B Pharmaceuticals Gmbh Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof
EP4297804A1 (en) * 2021-02-26 2024-01-03 Telix Pharmaceuticals (Innovations) Pty Ltd Solid phase synthesis of glutamate-urea-lysine derived (gul derived) prostate-specific membrane antigen (psma) targeting conjugates and their use as precursors for therapeutic and / or diagnostic agents
WO2023019303A1 (en) * 2021-08-17 2023-02-23 Clarity Pharmaceuticals Ltd Radiopharmaceuticals, methods for the production thereof, and uses in treatment, diagnosis and imaging diseases
AU2022396942A1 (en) * 2021-11-24 2024-05-23 Clarity Pharmaceuticals Ltd Compounds and compositions thereof for the treatment of cancer
WO2024031153A1 (en) * 2022-08-11 2024-02-15 Clarity Pharmaceuticals Limited Dimeric radiopharmaceuticals, compositions thereof and uses thereof
WO2024064969A2 (en) 2022-09-23 2024-03-28 Nuclidium Ag High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP803899A0 (en) * 1999-01-05 1999-01-28 Australian National University, The Cryptate compounds and methods for diagnosis and therapy.
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
CA2745495C (en) * 2008-12-02 2017-07-18 The University Of Melbourne Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
AU2012278938A1 (en) * 2011-07-07 2013-03-07 Australian Nuclear Science And Technology Organisation Cryptate compounds
DK2788353T3 (da) * 2011-12-06 2022-08-15 Clarity Pharmaceuticals Ltd Bur-aminligander til metallo-radiofarmaceutika
CN103638536B (zh) * 2013-12-11 2016-06-22 东南大学 一种分子探针及其制备方法和应用

Also Published As

Publication number Publication date
US20230382918A1 (en) 2023-11-30
MX2022002401A (es) 2022-03-22
WO2018223180A1 (en) 2018-12-13
CN110914274B (zh) 2022-08-26
US11970503B2 (en) 2024-04-30
JP2020522478A (ja) 2020-07-30
EP3634965A4 (en) 2021-03-03
CA3066525A1 (en) 2018-12-13
PT3634965T (pt) 2023-04-20
DK3634965T3 (da) 2023-05-01
RU2019144070A (ru) 2021-07-12
AU2018280338A1 (en) 2019-12-19
CN115322244A (zh) 2022-11-11
US20220315596A1 (en) 2022-10-06
JP2022184952A (ja) 2022-12-13
ES2943458T3 (es) 2023-06-13
US20220041608A1 (en) 2022-02-10
US10975089B2 (en) 2021-04-13
US20200095257A1 (en) 2020-03-26
CN110914274A (zh) 2020-03-24
JP7144451B2 (ja) 2022-09-29
PL3634965T3 (pl) 2023-08-07
US11384088B2 (en) 2022-07-12
FI3634965T3 (fi) 2023-05-04
EP3634965B1 (en) 2023-02-22
KR102644075B1 (ko) 2024-03-07
RU2019144070A3 (es) 2021-09-28
KR20200011950A (ko) 2020-02-04
AU2018280338B2 (en) 2021-07-15
EP3634965A1 (en) 2020-04-15
EP4209495A1 (en) 2023-07-12
BR112019025881A2 (pt) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2022002401A (es) Productos radiofarmaceuticos, agentes de radioimagenologia,y uso de los mismos.
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
MX2022014611A (es) Compuestos para tomografia por emision de positrones.
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
MX2017003886A (es) Conjugado radiofarmaceutico de un metabolito y un agente epr para tratar celulas tumorales.
SA518391121B1 (ar) 18f مثبطات موسومة بواسطة (psma) في مستضد الغشاء الخاص بالبروستاتا واستخدامها كعوامل تصوير تشخيصي لحالات سرطان البروستاتا
MX2015008993A (es) Radiofarmaceuticos y agentes de radio-formacion de imagen a base de triazina.
EA201891444A1 (ru) ЛИГАНДЫ mGluR2/3 ДЛЯ PET, МЕЧЕННЫЕ РАДИОАКТИВНЫМИ ИЗОТОПАМИ
MX2023005053A (es) Ligandos de psma para la formacion de imagenes y endorradioterapia.
MX2019005144A (es) Tratamiento de cáncer de mama positivo para her2.
JP2014508784A5 (es)
MX2018006226A (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
MX2021014292A (es) Formulaciones de agentes de imagen de psma.
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
WO2015042446A3 (en) Compositions and methods for the analysis of radiosensitivity
WO2013113801A3 (en) Chelating agents
MX2017010625A (es) Alfa-1-microglobulina para usarse en la proteccion de los riñones en terapia con radionucleidos.
WO2019126594A3 (en) Antibodies to centrin-1, methods of making, and uses thereof
SG11201911602RA (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof
NZ758917A (en) Compounds for positron emission tomography